natgillin/translations-raw huggingface dataset:
Type 1 farveløst glas cylinderampul med et sort stempel (bromobutyl gummi) og en ombøjet hætte (aluminium) med en prop (bromobutyl eller laminat af polyisopren og bromobutyl gummi) indeholdende 3 ml opløsning.
Type 1 colourless glass cartridge with a black plunger (bromobutyl rubber) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber) containing 3 ml of solution.
Type 1 farveløst glas cylinderampul med et sort stempel (bromobutyl gummi) og en ombøjet hætte, (aluminium) med en prop (bromobutyl eller laminat af polyisopren og bromobutyl) indeholdende 3 ml opløsning.
Type 1 colourless glass cartridge with a black plunger (bromobutyl rubber) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber) containing 3 ml of solution.
Type 1 farveløst glas cylinderampul med et sort stempel (bromobutyl gummi) og en ombøjet hætte, (aluminium) og en prop (bromobutyl eller laminat af polyisopren og bromobutyl gummi) indeholdende 3 ml opløsning.
Type 1 colourless glass cartridge with a black plunger (bromobutyl rubber) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber) containing 3 ml of solution.
Type 1 glas-cylinderampuller, forseglede med klorobutyl-gummimembraner og stempler og sikrede med aluminiumforseglinger.
Type I glass cartridges, sealed with chlorobutyldisc seals and plunger heads and secured with aluminium seals.
Type 1 hætteglas med en silikoneret, grå bromobutylprop og et aluminiumssegl, med et anvendeligt volumen på 10 ml (20 mg) eller 25 ml (50 mg).
Type I glass vials, each with a siliconised grey bromobutyl stopper, and an aluminium seal, with a deliverable volume of 10 ml (20 mg) or 25 ml (50 mg).
Type 1-diabetes
Type 1 diabetes mellitus
Type 1-diabetes (C-peptid-negativ)
Type 1 diabetes (C-peptide negative)
type 1-diabetes (sukkersyge), som kan inkludere øget appetit eller tørst, hyppigere vandladning eller vægttab
type 1 diabetes, which may include feeling more hungry or thirsty than usual, need to urinate more often or weight loss
type 1-diabetes (sukkersyge); nedsat indhold af natrium, kalium og kalcium i blodet
type 1 diabetes; decreased sodium, potassium and calcium in the blood
type 1-diabetes mellitus
Type 1 diabetes mellitus
type 1-diabetes mellitus (diabetisk ketoacidose)
type 1 diabetes mellitus (diabetic ketoacidosis)
type 1-diabetes mellitusd, hyponatriæmi, hypokaliæmi, hypokalcæmi
type 1 diabetes mellitusd, hyponatraemia, hypokalaemia, hypocalcaemia
Type 1-diabetes.
type 1 diabetes
Type 1-diabetikere skal fortsætte med at indtage i det mindste små mængder af kulhydrater (mad eller drikke) regelmæssigt, også selv om de kun kan spise lidt eller ingen føde, kaster op, etc. og de må aldrig udelade insulin helt.
Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates (food or beverage) on a regular basis; even if they are able to eat only little or no food, or are vomiting, etc., and they must never omit insulin entirely.
Type 2 (MEF-1) 8 D antigen-enheder4
Type 2 (MEF-1) 8 D antigen units4
Type 2 (MEF-1) 8 D-antigen-enheder5
Type 2 (MEF-1) 8 D antigen units5
Type 2 diabetes mellitus
Type2 diabetes mellitus
Type 2- diabetes kaldes også ikke- insulinkrævende diabetes mellitus eller gammelmandssukkersyge.
Type 2 diabetes is also called non-insulin-dependent diabetes mellitus or NIDDM.
Type 2-diabetes
Type 2 diabetes mellitus
Type 2-diabetes kaldes også ikke- insulinkrævende diabetes mellitus eller gammelmandssukkersyge.
Type 2 diabetes is also called non-insulin-dependent diabetes mellitus or NIDDM.
Type 2-diabetes kaldes også ikke-insulin-afhængig diabetes mellitus eller NIDDM.
Type 2 diabetes is also called non-insulin-dependent diabetes mellitus, or NIDDM.
Type 2-diabetes kaldes også ikke-insulinkrævende diabetes mellitus eller gammelmandssukkersyge.
Type 2 diabetes is also called non-insulin-dependent diabetes mellitus or NIDDM.
type 2-diabetes mellitus (ikke-insulinkrævende sukkersyge), når metformin ikke er egnet eller ikke har haft tilstrækkelig virkning.
It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus, when metformin is not suitable or has failed to work adequately.
Type 2-diabetes mellitus, nedsat glucosetolerance
Type 2 diabetes mellitus, glucose tolerance impaired
Type 3 (Saukett) 32 D antigen-enheder4
Type 3 (Saukett) 32 D antigen units4
Type 3 (Saukett) 32 D-antigen-enheder5
Type 3 (Saukett) 32 D antigen units5
Type AE Type C Andetc
Type AE Type C Otherc
Type B natriuretisk peptid (BNP)- niveauet blev nedsat med 25 % i Enviage-armen sammenlignet med placebo.
B-type natriuretic peptide (BNP) levels were reduced by 25% in the Enviage arm compared to placebo.
Type B natriuretisk peptid (BNP)- niveauet blev nedsat med 25 % i Tekturna-armen sammenlignet med placebo.
B-type natriuretic peptide (BNP) levels were reduced by 25% in the Tekturna arm compared to placebo.
Type C (stamme 578) betatoxoid  20 IE2
Type C (strain 578) beta toxoid ≥20 IU2
Type hudlidelse
Type of skin impairment
Type I
Type I glass
Type I brune hætteglas med chlorobutyl-gummiprop og en aluminiumshætte.
Type I amber glass vial with a chlorobutyl rubber stopper and an aluminium cap.
Type I farveløst hætteglas (8 ml), med grå brombutylprop og aluminiumsforsegling med plastik flip- off låg indeholdende 4 mg topotecan.
Type I colourless glass vial (8 ml), with grey bromobutylic stopper and aluminium seal with plastic flip-off cap containing 4 mg topotecan.
Type I glas fyldt injektionssprøjte.
Type I glass pre-filled syringe.
Type I glas hætteglas enten 10 ml eller 15 ml med chlorobutyl gummiprop, forseglet med aluminiumshætte.
Type I glass vial of either 10 ml or 15 ml with chlorobutyl rubber stopper sealed with an aluminium flip- off seal.
Type I glas hætteglas enten 5 ml eller 20 ml med butyl gummiprop, forseglet med aluminiumshætte.
Type I glass vial of either 5 ml or 20 ml with butyl rubber stopper sealed with an aluminium flip-off seal.
Type I glas med en butylelastomerprop, forseglet med en aluminiumshætte.
Type I glass vial with a butyl elastomer closure, sealed with an aluminium cap.
Type I glasflaske
Vial (glass)
Type I glasflaske (10 doser) eller type II glasflaske (50 doser) med butylelastomer prop.
Type I glass bottle (10 doses) or type II glass bottle (50 doses) with butyl elastomer closure
Type I glasflaske lukket med en butyl elastomer prop og forseglet med en aluminiums eller plast kapsel
Type I glass bottle closed with a butyl elastomer closure and sealed with an aluminium or plastic cap
Type I glasflaske à 10 ml med butylelastomer-prop.
Type I glass bottle of 10 ml with butyl elastomer closure.
Type I glasflasker eller propylen (kun til 50 ml emulsion) hætteglas med en butyl/nitryl elastomer- prop, forseglet med en aluminiumshætte.
Type I glass or polypropylene (for emulsion of 50 ml only) vials with a butyl/nitryl elastomer closures and sealed with an aluminium cap
Type I hydrolytisk hætteglas af glas med butylprop og aluminiumshæt te
Type I hydrolytic glass vial with butyl stopper and aluminium seal.
Type I hætteglas (gummiprop og aluminium låg)
Type I glass vial (rubber stopper and aluminium cap)
Type I hætteglas indeholdende 0,8 ml solvent.
Type I glass vials containing the 0.8 ml of solvent.
Type I hætteglas med 1 dosis vaccine.
Type I glass vials containing 1 dose of vaccine;
Type I) med prop af butylgummi og aluminiumkapsel.
Type I clear glass), closed with a stopper (butyl rubber) and seal (aluminium).
type I- hætteglas
Injection vial (type I glass)
Type I-glascylinder (1 ml), hvorpå er monteret en kanyle 27 gauge og længde 12,7 mm tilproppet med en bromobutyl eller chlorobutyl elastomerprop.
Type I glass barrel (1 ml) affixed with a 27 gauge x 12.7 mm needle and stoppered with a chlorobutyl elastomer plunger stopper.
Type I-glasflaske
Type I glass bottle
Type I-hætteglas af farveløst glas indeholdende 5 ml (10 doser) eller 20 ml (40 doser).
Type I colourless glass vials with5 ml (10 doses) and 20 ml (40 doses).
Type I-hætteglas af klart glas med en latexfri gummiprop af bromobutyl og forsegling af aluminium, som indeholder 5 ml koncentrat til infusionsvæske, opløsning.
Clear Type I glass vial with a latex-free bromobutyl rubber stopper and aluminium over-seal, containing 5 ml of concentrate for solution for infusion.
Type I-hætteglas af klart glas med en latexfri gummiprop af bromobutyl og forsegling af aluminium, som indeholder 50 ml koncentrat til infusionsvæske, opløsning.
Clear Type I glass vial with a latex-free bromobutyl rubber stopper and aluminium over-seal, containing 50 ml of concentrate for solution for infusion.
Type I-hætteglas, der er lukket med en lamineret gummiprop og forseglet med en afrivelig aluminiumshætte.
Type-I glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
Type II diabetes (sukkersyge)
Type 2 diabetes
Type II glasflaske med butylelastomer-prop.
Type II glass bottle with butyl elastomer closure.
Type II hydrolytisk hætteglas af glas (EP) med butylprop og (EP)
hydrolytic glass vials type II (EP) with butyl stopper (EP) and aluminium seal
Type II hydrolytisk hætteglas af glas med butylprop og aluminiumshæt te
Type II hydrolytic glass vial with butyl stopper and aluminium seal
Type II hydrolytisk hætteglas af glas med butylprop og aluminiumshæt te
Type II hydrolytic glass vial with butyl stopper and aluminium seal.
Type III glasflaske med høj densitet polyethylen børnesikret skruelåg.
Type III glass bottle with high density polyethylene tamper evidence screw cap.
Type og mønster af de maligniteter, som blev rapporteret i den åbne periode i forsøgene, svarede til dem, der blev rapporteret i den dobbeltblinde periode.
The type and pattern of malignancies reported during the open-label period of the trials were similar to those reported for the double-blind experience.
Type-1 glas med chlorbutyl-gummilukkere og forseglede med aluminium ”flip-off”-kapsler.
Type I glass vial with chlorobutyl rubber stopper and sealed with aluminium flip-off cap.
Typen af bivirkninger var ens uanset alder.
The types of adverse events were similar regardless of age.
Typen af bivirkninger, som blev rapporteret i løbet af de første 7 behandlingsdage, svarende til dem, som blev rapporteret i den samlede behandlingsperiode.
The types of adverse reactions reported during the first 7 days of treatment were similar to those reported for the overall treatment period.
Typen af IAR’er svarede til den, der blev observeret i andre kliniske studier.
The type of IARs was similar to those seen in other clinical studies.
Typen af infektioner, som blev observeret i kliniske studier med patienter med juvenil, idiopatisk artrit i alderen 2 til 18 år, var generelt milde til moderate og svarende til dem, som almindeligvis ses hos ambulante, pædiatriske populationer.
The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years were generally mild to moderate and consistent with those commonly seen in outpatient paediatric populations.
typen af ‘sekale’lægemidler såsom dihydroergotamin, ergonovin, ergotamin eller methylergonovin – bruges ved migræneanfald og klyngehovedpine
‘ergot’ type medicines, such as dihydro-ergotamine, ergonovine, ergotamine or methylergonovine – used for migraine and cluster headaches
Typen og frekvensen af bivirkninger hos patienter med juvenil idiopatisk artrit var de samme som dem, man så i studier af Enbrel til voksne patienter med reumatoid artrit, og hovedparten var lette.
The types and proportion of adverse events in juvenile idiopathic arthritis patients were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the majority were mild.
Typer af hudkræft (basalcellekræft, nyt primært melanom)
Types of skin cancers (basal cell carcinoma, new primary melanoma)
Typer af IPD(1)
Types of IPD(1)
Typisk er sådanne reaktioner set inden for de første få uger eller måneder efter påbegyndelsen af CART.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Typisk udseende som hos en person, der får store mængder steroider, såsom måneansigt, tyrenakke, fedme på overkroppen
Typical appearance of a person with high levels of steroids, such as moon face, hump back, upper body obesity
Typisk var laboratorieobservationerne af proteinuri ikke progressive.
Typically, laboratory observations of proteinuria were not progressive.
Typiske behandlingsforløb fremgår herunder.
Typical courses of treatment are given below.
Typiske bivirkninger af NSAID’s (non-steroide antiinflammatoriske stoffer), så som appetitløshed, opkastning, diarré, fækal okkult blødning, lethargi og nyresvigt er af og til set.
Typical adverse drug reactions of non-steroidal anti-inflammatory drugs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Typiske bivirkninger for nonsteroide anti-inflammatoriske stoffer (NSAID) såsom tab af appetit, opkastning, diarré, fækalt okkult blod, apati og nyresvigt er lejlighedsvis blevet rapporteret.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Typiske bivirkninger fra non-steroide anti-inflammatoriske lægemidler (NSAID-præparater) så som appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er af og til set.
Typical adverse drug reactions of NSAIDS such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Typiske bivirkninger fra non-steroide antiinflammatoriske lægemidler (NSAID-præparater) så som appetitløshed, opkastning, diarré, fækal okkult blødning og apati er af og til set.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported.
Typiske doser er angivet herunder.
Typical doses are given below.
Typiske non-steroide anti-inflammatoriske (NSAID-præparater) bivirkninger så som appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er set lejlighedsvist.
Typical adverse reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Typiske non-steroide anti-inflammatoriske (NSAID-præparater) bivirkninger såsom appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er set lejlighedsvist.
Typical adverse reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Typiske NSAID-bivirkninger så som appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er set lejlighedsvist.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Typiske NSAID-bivirkninger såsom appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er set lejlighedsvist.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Typiske NSAID-bivirkninger, så som appetitløshed, opkastning, diarré, fækal okkult blødning og apati er af og til set.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported.
Typiske NSAID-bivirkninger, så som appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er af og til set.
Typical adverse drug reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Typiske NSAID-bivirkninger, så som appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er af og til set.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Typiske NSAID-bivirkninger, så som appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er af og til set.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood lethargy and renal failure have occasionally been reported.
Typiske NSAID-bivirkninger, så som appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er af og til set.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Typiske NSAID-bivirkninger, så som appetitløshed, opkastning, diarré, fækal okkult blødning, apati og nyresvigt er af og til set.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Typiske NSAID-bivirkninger, så som appetitløshed, opkastning, diarré, fækal okkult blødning, lethargi og nyresvigt er af og til set.
Typical adverse drug reactions of non-steroidal anti-inflammatory drugs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Typiske uønskede bivirkninger ved non-steroide anti-inflammatoriske præparater (NSAID-præparater) som f.eks. tab af appetit, opkastning, diarré, blod i afføringen, apati og nyresvigt er lejlighedsvis rapporteret.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Typiske uønskede bivirkninger ved NSAID-præparater som f.eks. tab af appetit, opkastning, diarré, blod i afføringen, apati og nyresvigt er lejlighedsvis rapporteret.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Tyramin/safinamid interaktion
Tyramine/safinamide interaction
Tyreoidea
Thyroid
tyrken af lægemidlet, der hæmmer knogleresorption (højere risiko for højpotente stoffer), administrationsvej (højere risiko for parenteral administration) og kumulativ dosis af knogleresorption behandling
Potency of the medicinal product that inhibit bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy
tyrken af lægemidlet, der hæmmer knogleresorption (højere risiko for højpotente stoffer), administrationsvej (højere risiko for parenteral administration) og kumulativ dosis af knogleresorption behandling
Potency of the medicinal product that inhibit bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy.
tyrken af lægemidlet, som hæmmer knogleresorptionen (øget risiko ved meget potente forbindelser), indgivelsesvej (øget risiko ved parenteral administration) samt den kumulative dosis af knogleresorptionsbehandlingen.
potency of the medicinal product that inhibits bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy.
Tyroidea
0.0469
Tyroiditis
Thyroiditis
tyrosinkinasehæmmere
inhibitors such as
tyrrelser
(bisphosphonat
tyrrelser
attention
tyrrelser
Status epilepticus
Tysabri anvendes til behandling af voksne med meget aktiv dissemineret sklerose (MS).
Tysabri is used to treat adults with highly active multiple sclerosis (MS).
Tysabri anvendes ved den form af MS, der kaldes recidiverende-remitterende multipel sklerose, hvor patienten har tilbagefald af symptomer (recidiv) ind mellem symptomfri perioder (remission).
Tysabri is used in the type of MS known as ‘relapsing-remitting’ MS, when the patient has attacks (relapses) in between periods with no symptoms (remissions).
Tysabri anvendt alene var mere effektivt end placebo til at reducere antallet af tilbagefald.
Tysabri used on its own was more effective than placebo in reducing the number of relapses.
Tysabri er et koncentrat, der blandes til en opløsning til infusion (drop i en vene).
Tysabri is a concentrate that is made up into a solution for infusion (drip) into a vein.
Tysabri gives hver fjerde uge ved en infusion, der varer en time.
Tysabri is given as a one-hour infusion every four weeks.
Tysabri må ikke gives til patienter, som har PML eller risiko for at pådrage sig infektioner, herunder patienter med svækket immunsystem.
Tysabri must not be given to patients who have PML or who are at risk of getting an infection, including patients whose immune systems are weakened.
TYSABRI skal fortyndes, inden du får det.
TYSABRI must be diluted before it is given to you.
TYSABRI-behandlingen skal initieres og kontinuerligt superviseres af speciallæger med erfaring i diagnosticering og behandling af neurologiske tilstande på hospitaler med let adgang til MR-scanning.
That TYSABRI therapy is to be initiated and continuously supervised by specialised physicians experienced in the diagnosis and treatment of neurological conditions, in centres with timely access to MRI.
Tyskland
D-85748 Garching Germany
Tyskland eller
North Rhine-Westphalia Germany or
Tyskland info@ratiopharm.de
Germany info@ratiopharm.de
Tyskland Middlesex TW8 9GS
Middlesex TW8 9GS
Tyskland.
Germany
Tyskland/Deutschland Cardiome UK Limited Tel: +49 (0)69 33 29 62 76
Germany/ Deutschland Cardiome UK Limited Tel: +49 (0)69 33 29 62 76
Tyve mildt til moderat immunkompromitterede børn og unge i alderen fra 5 til og med 17 år (der var i behandling med kemo- og/eller stråleterapi, eller som for nylig havde fået kemoterapi) blev randomiseret i forholdet 1:1 til trivalent Fluenz eller placebo.
Twenty mild to moderately immunocompromised children and adolescents 5 through 17 years of age (receiving chemotherapy and/or radiation therapy or who had recently received chemotherapy) were randomized 1:1 to trivalent Fluenz or placebo.
Tyve patienter (50%) oplevede leukocytose, men hos alle disse patienter var WBC-tallet faldende eller havde normaliseret sig på tidspunktet for knoglemarvsremissionen, og cytotoksisk kemoterapi eller leukoferese var ikke påkrævet.
Twenty patients (50%) experienced leukocytosis; however, in all these patients, the WBC count was declining or had normalized by the time of bone marrow remission and cytotoxic chemotherapy or leukopheresis was not required.
Tyverb (1.250 mg/dag) + capecitabin (2.000 mg/ m2/dag, dag 1-14 hver 21. dag)
Tyverb (1,250 mg/day)+ capecitabine (2,000 mg/m2/day, days 1-14 q21 days)
Tyverb anvendes til behandling af patienter med brystkræft, hvor der "udtrykkes" store mængder HER2.
Tyverb is used to treat patients with breast cancer that has been shown to be ‘expressing’ large amounts of HER2.
Tyverb blev oprindeligt godkendt under "særlige omstændigheder".
Tyverb was originally given ‘conditional approval’.
Tyverb blev undersøgt i tre hovedundersøgelser hos kvinder med brystkræft.
Tyverb was studied in three main studies involving women with breast cancer.
Tyverb er et kræftlægemiddel, som indeholder det aktive stof lapatinib.
Tyverb is a cancer medicine that contains the active substance lapatinib.
Tyverb er ikke indiceret som adjuverende behandling.
Tyverb is not indicated in the adjuvant setting.
Tyverb er ovale, bikonvekse, gule, filmovertrukne tabletter, der er præget "GS XJG" på den ene side.
Tyverb film-coated tablets are oval, biconvex, yellow film-coated, with ‘GS XJG’ marked on one side.
Tyverb fås også i plastikbeholdere med 70, 84, 105 eller 140 tabletter.
Tyverb is also available in plastic bottles containing 70, 84, 105 or 140 tablets.